Gadolinium-dependent contrast agents (GBCAs) are extensively used in magnetic resonance imaging (MRI) to improve the visibility of blood vessels, tumors, inflammation, and other interior structures. While generally thought of Safe and sound, considerations about GBCA toxicity have emerged in the last two decades—particularly in clients with impai